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A Short Antisense Oligonucleotide Ameliorates Symptoms of Severe
Mouse Models of Spinal Muscular Atrophy
Abstract
Recent reports underscore the unparalleled potential of antisense-oligonucleotide (ASO)-based approaches
to ameliorate various pathological conditions. However, in vivo studies validating the effectiveness of a short
ASO (<10-mer) in the context of a human disease have not been performed. One disease with proven
amenability to ASO-based therapy is spinal muscular atrophy (SMA). SMA is a neuromuscular disease caused
by loss-of-function mutations in the survival motor neuron 1 (SMN1) gene. Correction of aberrant splicing of
the remaining paralog, SMN2, can rescue mouse models of SMA. Here, we report the therapeutic efficacy of
an 8-mer ASO (3UP8i) in two severe models of SMA. While 3UP8i modestly improved survival and function
in the more severe Taiwanese SMA model, it dramatically increased survival, improved neuromuscular
junction pathology, and tempered cardiac deficits in a new, less severe model of SMA. Our results expand the
repertoire of ASO-based compounds for SMA therapy, and for the first time, demonstrate the in vivo efficacy
of a short ASO in the context of a human disease.
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Introduction
The survival motor neuron (SMN) gene is ubiquitously 
expressed and produces an essential protein.1 Low SMN 
levels cause spinal muscular atrophy (SMA) (OMIM 253300; 
253550; 253400; 271150), an autosomal recessive neuro-
muscular disease that is the leading hereditary cause of infant 
death.2,3 SMA is characterized by the loss of motor neurons 
within the spinal cord and resultant muscle weakness and 
atrophy.4 Clinically, SMA is heterogeneous, and patients are 
stratified into clinical types based on the age at disease-
onset and maximum motor function achievements.5–9 Geneti-
cally, SMA is homogeneous in that all forms of the disease 
are caused by the loss of function mutations within the SMN1 
gene, with concurrent retention of at least one copy of a highly 
similar gene, SMN2.2 SMN2 differs from SMN1 functionally by 
a single C to T nucleotide transition at position 6 (C6U transi-
tion in transcript) in exon 7 (ref. 10). The C6U transition creates 
a silencer and/or strengthens an inhibitory motif, which leads 
to a predominant amount of the transcripts skipping SMN2 
exon 7 (refs. 11,12), and reviewed in Singh et al.13 SMNΔ7, 
the translated product from exon 7-skipped transcripts, is less 
functional and rapidly degraded.14
A recent update on potential therapeutic options for SMA 
treatment identified antisense-oligonucleotide (ASO)-based 
therapy as one of the most promising strategies.15 Blocking 
of intronic splicing silencer N1 (ISS-N1) by an ASO fully cor-
rects SMN2 exon 7 splicing and restores a high level of SMN 
from endogenous SMN2.16 The original study performed with 
the ISS-N1 target employed a 20-mer ASO encompass-
ing uniform phosphorothioate backbone and 2′-O-methyl 
modifications (2′OMeP).16 Subsequent preclinical studies 
have revealed efficacy differences between ASO chemis-
tries and the route of ASO administrations.17 ASO-10–27, an 
18-mer ASO encompassing phosphorothioate backbone and 
2′-O-methoxyethyl modifications (abbreviated as “MOE”), 
has shown better efficacy when delivered peripherally but 
not when delivered through an intracerebroventricular (ICV) 
route.18 Twenty-mer or longer phosphorodiamidate morpho-
lino oligomers (abbreviated as “PMOs”) have shown unprec-
edented efficacies when delivered through the ICV route.19,20 
These findings underscore the challenge in selecting an opti-
mal ASO with the right size and chemistry. Short ASOs offer 
several advantages over longer ASOs, including low to zero 
tolerance for mismatch base pairing, reduced cost of synthe-
sis, and ease of modifications.21 Despite these advantages, 
the lack of a validated short target coupled with the possibility 
of rapid clearance from the bloodstream, have limited explor-
ing the in vivo efficacy of very short ASOs.
The lessons learnt from ISS-N1 as an antisense target 
underscore certain basic principles that could be exploited 
for the validation of additional targets for SMA therapy.16 For 
instance, any strong inhibitory element within an intronic 
sequence, sequestration of which does not interfere with down-
stream processes, could serve as an ideal antisense target. 
Incidentally, an eight-nucleotide GC-rich sequence (GCRS) 
partially overlaps with ISS-N1, and simultaneously participates 
in the formation of an internal stem formed by long-distance 
interaction (LDI), termed internal stem through LDI-1 (ISTL1), 
a unique inhibitory RNA structure.21,22 Sequestration of GCRS 
by an 8-mer ASO encompassing 2′OMeP (3UP8) fully corrects 
aberrant SMN2 exon 7 splicing and restores high levels of SMN 
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Recent reports underscore the unparalleled potential of antisense-oligonucleotide (ASO)-based approaches to ameliorate 
various pathological conditions. However, in vivo studies validating the effectiveness of a short ASO (<10-mer) in the context 
of a human disease have not been performed. One disease with proven amenability to ASO-based therapy is spinal muscular 
atrophy (SMA). SMA is a neuromuscular disease caused by loss-of-function mutations in the survival motor neuron 1 (SMN1) 
gene. Correction of aberrant splicing of the remaining paralog, SMN2, can rescue mouse models of SMA. Here, we report the 
therapeutic efficacy of an 8-mer ASO (3UP8i) in two severe models of SMA. While 3UP8i modestly improved survival and function 
in the more severe Taiwanese SMA model, it dramatically increased survival, improved neuromuscular junction pathology, and 
tempered cardiac deficits in a new, less severe model of SMA. Our results expand the repertoire of ASO-based compounds for 
SMA therapy, and for the first time, demonstrate the in vivo efficacy of a short ASO in the context of a human disease.
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in SMA patient cells.21 Encouraged by these findings, here we 
examine the therapeutic efficacy of 3UP8i, an improved ver-
sion of 3UP8 in two severe mouse models of SMA. Our results 
provide the first evidence of therapeutic efficacy of a very short 
ASO in the context of a preclinical study of a human disease.
Results
Optimization of an 8-mer ASO for in vivo application
We previously reported that an 8-mer 2′OMeP ASO (3UP8) 
that targets a GCRS that partially overlaps with ISS-N1 cor-
rects SMN2 exon 7 splicing in SMA patient cells (Figure 1c, 
lane 3).21 Unlike large ASOs, 3UP8 showed zero tolerance 
for single-nucleotide mismatch base pairing.21 Another 8-mer 
ASO (F8) that targeted the first eight residues of ISS-N1 had 
no effect on SMN2 exon 7 splicing, suggesting the effect of 
3UP8 is independent of ISS-N1 and specific to the GCRS 
(Figure 1c, lane 2).21 To test the in vivo efficacy of 3UP8, we 
performed preliminary experiments in healthy, adult Smn het-
erozygous mice containing human SMN2.23 Intraperitoneal 
(IP) administration of a moderate dose (20 μg/g body weight) 
of 3UP8 did not produce any noticeable effect on SMN2 exon 
7 splicing in the liver. Among several factors, the lack of the 
stimulatory effect of 3UP8 in vivo could be attributed to the 
fast clearance of a short ASO from the blood. To circumvent 
this problem, we generated 3UP8i, an improved version of 
3UP8 by incorporating PEG-282 and propyl modifications at 
the 5′ and 3′ ends, respectively (Figure 1b). These modifica-
tions confer enhanced stability and resistance to enzymatic 
degradation or modification.24,25 As expected, 3UP8i retained 
the GCRS-specific stimulatory effect on SMN2 exon 7 splicing 
in SMA patient cells (Figure 1c, lane 5). A control 8-mer ASO 
with similar modifications and a single-nucleotide substitu-
tion (CON8i) produced no appreciable effect on SMN2 exon 
7 splicing (Figure 1c, lane 4). In vivo, 3UP8i (20 μg/g body 
weight) showed noticeable stimulation of SMN2 exon 7 splic-
ing in liver (Figure 1d, lane 4). We next examined the effect 
of high dosages (80 μg/g body weight) of 3UP8i and CON8i 
delivered through IP and subcutaneous (SC) routes. 3UP8i 
showed substantial stimulation of SMN2 exon 7 inclusion in 
the liver, whereas CON8i had no noticeable effect (Figure 1d, 
lanes 5–10). Upon ICV administration of a moderate dose 
of 3UP8i, we observed substantial inclusion of SMN2 exon 
7 in neuronal tissues, with some concomitant peripheral 
increases as well (Supplementary Figure S1c). These initial 
experiments demonstrated that 3UP8i shows a wide range of 
in vivo function.
Figure 1  Effect of GC-rich sequence (GCRS)-targeting ASOs on splicing of SMN2 in vitro and in vivo. (a) Diagrammatic representation 
of annealing positions of ASOs targeting GCRS within SMN2 intron 7. Negative regulators of exon 7 splicing, GCRS, ISS-N1 and hnRNP A1 
binding sites are highlighted with boxes. Annealing positions of ASOs (3UP8, 3UP8i, CON8i, and F8) are shown as horizontal bars. Numbering 
of nucleotides starts from the first position of intron 7. (b) Sequences of ASOs used in this study. All ASOs employed for mouse studies had 
PEG-282 and propyl modifications at the 5′ and 3′ ends, respectively. (c) SMN2 exon 7 inclusion in SMA patient fibroblasts after transfection 
with various ASOs. (d) SMN2 exon 7 inclusion in the liver of heterozygous mice (Smn+/−; SMN2+/+) after treatment with various ASOs. Each 
ASO was administered by intraperitoneal (IP) or subcutaneous (SC) route at the indicated dose. Exon 7-included and exon 7-skipped products 
are indicated as FL and Δ7, respectively.
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In vivo efficacy of 3UP8i in severe 5058-Hemi SMA mice
To examine the in vivo efficacy of 3UP8i, we employed the 
“Taiwanese” severe SMA mouse model, which we refer to as 
5058-Hemi SMA mice.26 This model harbors two copies of the 
SMN2 transgene and a targeted mutation of murine Smn exon 
7 (ref. 27). Previous studies established that early, peripheral 
ASO delivery was more effective than an ICV delivery strat-
egy for long-term rescue of the SMA phenotype in this SMA 
model.18 Thus, in blinded studies, we administered 3UP8i via 
IP injection starting at postnatal day 0 (P0), with two subse-
quent doses at P5 and P10. Both low (20 μg/g body weight) 
and high (80 μg/g body weight) doses were tested to assess 
the dose-dependent effect (Figure 2). The low dose of 3UP8i 
produced no apparent benefit in terms of survival or weight 
gain compared to CON8i, although a significant improve-
ment in righting reflex was seen by P9 (Figure 2a–c). At 
the higher dose, 3UP8i resulted in a modest, yet statistically 
significant increase in weight gain starting at P8 compared 
to the CON8i-treated 5058-Hemi SMA mice (Figure 2a). 
 Compared to heterozygous littermates, the 3UP8i-treated 
SMA mice were still noticeably underdeveloped (Figure 2d). 
The higher 3UP8i dose also resulted in a significant increase 
in median survival compared to CON8i, from 10 to 13 days 
(Figure 2b). Although general mobility was diminished, 
motor function of 3UP8i-treated SMA mice, as assayed by 
the time-to-right, was indistinguishable from heterozygous 
controls (Figure 2c). Overall, although 3UP8i showed mod-
est efficacy, it did not produce the level of therapeutic efficacy 
seen with the longer ASOs in the same model.18
Effect of 3UP8i on SMN2 exon 7 splicing is age-dependent
Based on the modest improvements in survival and func-
tion of 5058-Hemi SMA mice treated with 3UP8i, we pos-
tulated that 3UP8i might possess developmentally variable 
efficacy. To test this, we examined the ability of 3UP8i to 
increase full-length SMN2 (FL-SMN2) transcripts over time. 
We used homozygous 5058-SMA mice, which harbor four 
copies of SMN2 on a Smn mutant background; other than 
mild peripheral necrosis, they are phenotypically akin to unaf-
fected wild-type mice.27–29 Quantitative RT-PCR  (qRT-PCR) 
of liver samples from 5058-homozygous mice administered 
3UP8i or CON8i revealed that 3UP8i had limited SMN2 exon 
Figure 2 3UP8i modestly improves weight, survival, and righting reflex in severe SMA mice. 5058-Hemi FVB/N SMA mice (SMN2tg/o; 
Smntm1Hung/tm1Hung) were administered three doses at P0, P5, P10 of 3UP8i or mismatch control (CON8i) by IP injection (HET, n = 5; SMA-3UP8i 
(20 μg/g body weight), n = 5; SMA-3UP8i (80 μg/g body weight), n = 7; SMA-CON8i, n = 5). (a) SMA mice treated with 3UP8i show improved 
weight over CON8i-treated SMA mice. Values show as mean ± SEM. *P = 0.04825, **P = 0.0231, Student’s t-test. (b) Kaplan–Meier survival 
curve. The median survival of pairwise comparison between 3UP8i (80 μg/g body weight) and CON8i-treated SMA mice was significantly 
different, by log-rank test, P = 0.00260. Median survival, HET = undefined (n = 5); 3UP8i (80 μg/g body weight) = 13 d (n = 7); 3UP8i (20 μg/g) = 8 d 
(n = 5); CON8i = 10 d (n = 5). (c) Righting reflex. Righting time ≥60 seconds considered a failed test. Data presented as a mean ± SEM. *P = 
0.02761, Student’s t-test. (d) Representative image of a P11 SMA mouse treated with 3UP8i at 80 μg/g body weight shown alongside a 
littermate control (HET).
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7 splice-correcting activity at early postnatal time points 
(P2: 3UP8i, 1.55 ± 0.180; CON8i, 0.876 ± 0.126) (Figure 3a, 
left panel). At later time points, 3UP8i displayed a substan-
tial increase in FL-SMN2 transcript relative to CON8i (P10: 
3UP8i, 2.12 ± 0.153; CON8i, 0.759 ± 0.437. P15: 3UP8i, 
3.88 ± 0.128; CON8i, 2.73 ± 0.115). End-point PCR of the 
same samples showed a similar pattern (Figure 3b). The 
qRT-PCR analysis at P20 showed only a modest increase 
of FL-SMN2 transcripts (P20: 3UP8i, 1.38 ± 0.124; CON8i, 
0.974 ± 0.085). However, the end point PCR analysis at P20 
showed the highest ratio of FL:Δ7 transcripts of any time-
point (Figure 3b, panel 4). The Δ7 transcripts of the CON8i-
treated samples were significantly higher for all time-points 
except P2 (Figure 3a, right panel). These results confirmed 
that SMN2 exon 7 inclusion by 3UP8i is age-dependent.
Effect of 3UP8i in a less severe mouse model of SMA
5058-Hemi SMA mice are one of the more severe models of 
SMA, with a limited therapeutic window.18,26,27 Knowing that 
the current formulation of 3UP8i is not entirely suitable for 
such early interventions, we developed an SMA mouse with 
a slightly larger therapeutic window. This new SMA model, 
termed 5058-Hemi hybrid, was generated using the same 
breeding strategy for 5058-Hemi SMA mice, except instead 
of intercrossing 5058 homozygous FVB/N mice with the out-
bred Δ7Smn allele from this line (Smntm1Hung), we used a dif-
ferent, but equivalent, Δ7Smn allele (Smntm1.1Jme) in a C57/
BL6 background (Smntm1.1Jme).27,30 By generating an F1 SMA 
hybrid, we more than doubled the median survival (P8 versus 
P22), and the age at which weight differentiated from controls 
(P4 versus P8) (Figure 4).
Using the same dosing strategy as with 5058-Hemi SMA 
mice, the median survival of 3UP8i-treated Hemi-hybrid SMA 
mice was undefined at study end point (P50), whereas the 
median survival of CON8i-treated Hemi-hybrid SMA was 
16 days. This represented at least a threefold increase in 
median survival of the 3UP8i-treated SMA mice (log rank, P < 
0.0001) (Figure 4b). Untreated SMA mice had a median sur-
vival of 22 days, which was significantly better than CON8i-
treated SMA mice (log rank, P = 0.0016), and likely due to 
a larger sampling size in conjunction with the stress of dos-
ing the CON8i-treated SMA mice. Alternatively, the CON8i 
ASO may not have been well tolerated, as there was also a 
small decrease in overall weight compared to the untreated 
Figure 3 3UP8i splicing efficacy is age-dependent. 5058-4copy mice (SMN2tg/o; SMN2tg/o) were administered 3UP8i (80 μg/g body weight, 
once daily) of or mismatch control (CON8i) starting at days P0, P8, P13, and P18. Liver was harvested at P2, P10, P15, and P20 was analyzed 
via qRT-PCR for full-length (FL) SMN2 (Left Panel) and Δ7-SMN2 (Right Panel). (a) SMN2 exon-7 inclusion. SMN2 levels were normalized to 
Gapdh. Data presented as mean fold change (log2−ΔΔCt) of 3UP8i relative to untreated ± S.D, n = 3 at each time point. Student’s t-test, **P < 
0.01, N.S., not significant. (b) FL- and Δ7-SMN2 end point RT-PCR of samples analyzed in (a). Exon 7-included and exon 7-skipped products 
are indicated as FL and Δ7, respectively.
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Figure 4 3UP8i improves pathology and survival in 5058-Hemi hybrid SMA mice. Hemi-hybrid SMA mice (SMN2tg/o;Smntm1Hung/tm1.1Jme) 
were administered three doses (80 μg/g body weight at P0, P5, P10) of 3UP8i or mismatch control (CON8i) by IP injection. (a) Representative 
images of SMA mice treated with 3UP8i (P12, middle panel; P26, right panel) or CON8i (left panel). Red arrow highlights severe hind limb 
edema in the CON8i-treated SMA mice. Note necrosed tail (right panel). (b) Kaplan–Meier survival curve. The median survival of pairwise 
comparison between 3UP8i- and CON8i-treated SMA mice was significantly different, by log-rank test, P < 0.0001. Median survival, HET = 
undefined (n > 20); SMA-3UP8i = undefined at P50 (n = 12); SMA- CON8i = 16 days (n = 11); SMA-untreated (Unt.) = 22 days (n = 19). (c) 
Weight of 5058 Hemi-hybrid SMA mice treated with 3UP8i increases compared to CON8i-treated mice (HET, n > 20; SMA-3UP8i, n = 12; 
SMA-CON8i, n = 11, SMA-Unt., n = 19). Data presented as mean ± SEM. *P = 0.028456, Student’s t-test. (d) SMN2 exon-7 inclusion. Liver 
was harvested at P12 or P50, and analyzed via qRT-PCR for full-length FL-SMN2 (left Panel) and Δ7-SMN2 (right panel). SMN2 levels were 
normalized to Gapdh. Data presented as fold change (log2−ΔΔCt) ± S.D. (n = 4) relative to either untreated (P12) or HET (P50). Student’s t-test, 
**P = 0.00000003 (FL); P = 0.00004661 (Δ7). (e) FL- and Δ7-SMN2 end point RT-PCR of samples analyzed in (d). (f) Liver was harvested at 
P12 or P50, and subjected to immunoblot with α-SMN and α-tubulin antibodies. (g) SMN levels were normalized to tubulin. Data presented 
as mean ± S.D. (n = 3). Student’s t-test, *P = 0.0018, **P = 0.0001; N.S., not significant. Unt., untreated.
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Hemi-hybrid SMA mice (Figure 4c). The study end point at 
P50 was chosen since the frequency of the 3UP8i-treated 
deaths had slowed substantially, and no further decline in 
health or motor function was evident. Moreover, we found 
that 3UP8i treatment resulted in a significant improvement 
in weight gain of 5058-Hemi hybrids, starting at P13 (3UP8i, 
6.19g ± 0.457; CON8i, 5.03 ± 0.322) (Figure 4c). This trend 
continued, and the slope of weight gain was similar to control 
mice.
Since heart defects and bradyarrythmia had been noted 
in other SMA mouse models,31–34 we studied the ECG wave-
forms of 5058-Hemi hybrid mice. Recording intervals were 
limited to preweaning ages due to post-weaning variabil-
ity between the sexes.35 By P10, heterozygote littermates 
diverged from all SMA mice for heart rate (HR) and PR 
interval (Supplementary Figure S2a and c, respectively). 
The 3UP8i-treated SMA mice displayed significant improve-
ment in HR by P18 (bpm: HET, 776 ± 11.2; 3UP8i, 701 ± 31.9; 
CON8i, 608 ± 39.3; Supplemenatry Figure S2a). The lower 
HR and elongated PR interval (ms: HET, 23.31 ± 0.459; 
3UP8i, 26.4 ± 0.930; CON8i, 30.43 ± 2.49) confirmed that this 
model presents with bradyarrythmia, although to a lesser 
extent than in the more severe, 5025-Δ7 model and severe 
inducible SMA mice.32,33 The QRS interval of the SMA pups 
was slightly elevated compared to control (HET, 9.69 ± 0.211; 
3UP8i, 10.7 ± 0.594; CON8i, 10.75 ± 0.543) (Supplementary 
Figure S2d). This elevation was indicative of delayed ven-
tricular depolarization times, and suggested a bundle branch 
block.36 Treatment with 3UP8i resulted in a corrective, down-
ward trend toward heterozygote levels, but it did not reach 
statistical significance compared to CON8i-treated SMA mice 
by P18. No significant difference was observed in heart rate 
variability (HRV) between SMA mice and control littermates 
(Supplementary Figure S2b). Together, the bradyarrythmia 
and heart block suggested that the 5058-Hemi hybrid SMA 
mice suffer from deficits in sympathetic innervation, and to 
some extent, 3UP8i was able to correct this.
One property of this particular model is the appearance of 
hind limb edema and tail necrosis, starting at ~P8 in untreated 
mice (Figure 4a, left panel). Treatment with 3UP8i prevented 
hind limb edema, and delayed tail necrosis  (Figure 4a, mid-
dle panel). Although the tail eventually necrosed in treated 
mice, they were generally spared from any additional periph-
eral necrosis (Figure 4a, right panel). Further, 3UP8i-treated 
SMA mice did not show any noticeable deficits in motor func-
tion over the course of the study.
The primary mode-of-action of 3UP8i is to promote the 
inclusion of exon 7 in SMN2 transcripts. Thus, we expected 
the levels of FL-SMN2 transcripts to substantially increase in 
the surviving 5058-Hemi hybrid SMA population that received 
3UP8i. We examined the relative SMN2 expression levels in 
the liver of 5058-Hemi hybrid mice by TaqMan qRT-PCR, 
and found that 2 days postfinal dose, 3UP8i-treated liver 
samples showed a fourfold increase in FL-SMN2 transcripts 
compared to CON8i-treatment (3UP8i, 5.95 ± 0.220; CON8i, 
1.40 ± 0.113) (Figure 4d, left panel). Correspondingly, the exon 
Figure 5 3UP8i improves NMJ pathology. 5058-Hemi hybrid SMA mice (SMN2tg/o;Smntm1Hung/tm1.1Jme) were administered three doses (80 μg/g 
body weight at P0, P5, P10) of 3UP8i or mismatch control (CON8i) by IP injection (n = 4, n > 50 NMJs/pup). (a) Whole mount NMJ analysis 
of P12 intercostal (IC) muscles stained with neurofilament H (NF-H)/synaptic vesicle 2 (SV2) (green), and α-Bungarotoxin (BTX) (red). Scale 
bar = 10 μm. (b) Quantification of IC innervation status. Data presented as mean ± SEM. Two-way analysis of variance repeated measures, 
with Bonferroni posthoc comparisons (*P = 0.0128, **P = 0.0002, ***P = 0.0001). Asterisks above error bars indicate significance relative to 
untreated control (HET); asterisks above line indicate significance between 3UP8i and CON8i-treated SMA mice. (c) Quantification of IC motor 
end plate area. Data are presented as mean ± SEM; N.S., not significant.
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7-skipped isoform (Δ7-SMN) significantly decreased three-
fold (3UP8i, 0.591 ± 0.117; CON8i, 1.78 ± 0.190) (Figure 4d, 
right panel). By P50, there was no significant difference in 
amount of FL-SMN2 and Δ7-SMN2 transcripts between 
3UP8i-treated SMA mice and untreated heterozygotes 
( Figure 4d). This suggested that the pharmacodynamic 
range of 3UP8i is less than 40 days in vivo. End-point PCR 
of the same samples confirmed the trend seen via qRT-PCR, 
with a noticeable increase in the FL-versus Δ7-SMN2 tran-
script ratio following 3UP8i treatment at P12 (Figure 4e). 
Previous studies have demonstrated that peripheral adminis-
tration of ASOs produces a splice-correction that is generally 
most pronounced in the liver, with other peripheral tissues 
displaying a reduced response.18 Examination of FL-SMN2 
levels in the quadriceps of 3UP8i-treated mice revealed con-
sistent findings. FL-SMN2 levels were elevated compared to 
CON8i-treated mice, although less than the change seen in 
the liver (Supplementary Figure S3a, b).
Ultimately, SMA is caused by a deficiency in SMN pro-
tein levels. Therefore, we determined whether the increases 
seen at the transcript level in the liver of 3UP8i-treated 
5058-Hemi hybrid SMA mice translated to increased levels 
of SMN. Compared to CON8i-treated mice, 3UP8i treatment 
resulted in nearly a threefold increase in SMN levels (HET, 
1.821 ± 0.133; CON8i, 0.441 ± 0.096; 3UP8i, 1.317 ± 0.183) 
(Figure 4g). These increased levels persisted through P50, 
although they were substantially lower compared to heterozy-
gous littermates (HET, 3.205 ± 0.177; 3UP8i, 1.683 ± 0.311). 
As expected, the decreased levels of FL-SMN2 transcripts 
from P12 to P50 translated to lower SMN levels (Figure 4f,g). 
However, the SMN levels from 3UP8i-treated mice were still 
much higher at P50 than the levels of CON8i-treated mice 
at P12. Moreover, SMN levels were also elevated in muscle, 
albeit to a smaller extent than in the liver (Supplementary 
Figure S3c,d). Taken together, the SMN protein levels and 
SMN2 exon 7 splicing data verified the molecular basis for 
the improved survival and function in the 5058-Hemi hybrid 
SMA mice.
Effect of 3UP8i on neuromuscular junction pathology
SMA is characterized as a disease of the motor unit, and 
viable therapeutics should improve synaptic and muscular 
pathologies. To examine possible improvements in motor unit 
pathology following 3UP8i treatment, we analyzed the neu-
romuscular junction (NMJ) of intercostal (IC) muscles from 
P12 5058-Hemi hybrid SMA mice (Figure 5a). IC muscles 
are critical for maintaining proper respiratory function, and 
are one of the more vulnerable muscle groups in both SMA 
mouse models and human SMA patients.37–39 The ICs from 
CON8i-treated SMA mice showed a significant decrease in 
fully innervated motor endplates (CON8i, 62.00% ± 1.780 
versus HET, 86.25% ± 2.18) with a concomitant increase 
in partial innervations (CON8i, 36.00% ± 3.34 versus HET, 
13.75% ± 2.18) (Figure 5b). Treatment with 3UP8i signifi-
cantly increased the percentage of fully innervated endplates 
relative to CON8i-treated SMA mice (3UP8i, 77.25% ± 1.93 
versus CON8i, 62.00% ± 1.780); and accordingly, brought 
partial innervations back toward those observed in control 
mice (HET, 13.75% ± 2.18; 3UP8i, 21.50% ± 2.10; CON8i, 
36.00% ± 3.34) (Figure 5b). There was no change in motor 
end plate size (Figure 5c). These results indicated an inher-
ent defect in either the formation and/or maintenance of the 
NMJ within the 5058-Hemi hybrid SMA mice, which was 
responsive to 3UP8i treatment.
Discussion
Recent preclinical studies employing ASO-based strategies 
aimed at SMN2 exon 7 splicing correction have achieved 
important milestones for the treatment of SMA, the lead-
ing genetic cause of infant mortality. While 18-mer or larger 
ASOs have been successfully employed in preclinical and 
clinical studies for the potential treatment of several diseases 
including SMA, in vivo studies that demonstrate the thera-
peutic potential of a splice-switching short ASO have yet to 
be completed. The only in vivo study reported thus far with 
a short ASO pertains to an 8-mer locked nucleic acid (LNA) 
against the seed sequence of a microRNA.40 Interestingly, an 
iso-sequential 8-mer ASO with 2′OMeP modifications target-
ing the same microRNA turned out to be totally ineffective.40  
Although interesting, these findings indicated a limited scope 
of a short ASO to the LNA-based chemistry. On the other 
hand, our earlier report that a GCRS-targeting 8-mer ASO 
(3UP8) could efficiently correct SMN2 exon 7 splicing in SMA 
patient cells suggested the therapeutic potential of the widely 
used 2′OMeP chemistry.21 However, despite stabilizing 
2′OMeP modifications, in vivo 3UP8 failed to correct SMN2 
exon 7 splicing. This was possibly due to terminal degrada-
tion and/or fast clearance from the blood. To combat these 
potential limitations, we explored chemistries that would con-
fer greater in vivo efficacy. 3UP8 with PEG-282 and C3-propyl 
terminal spacers (3UP8i) induced robust SMN2 exon 7 inclu-
sion in vivo, and a high level of specificity—the introduction 
of a single mismatch base in the middle of ASO completely 
eliminated the antisense response.
Bolstered by these initial results, we first tested the in vivo 
efficacy of 3UP8i in 5058-hemizygous mice, a severe model 
of SMA. A high dose (80 μg/g body weight) of 3UP8i, we 
observed an encouraging trend of body weight gain, improved 
righting reflex, and a modest 3-day extension in survival of 
these severe mice. The outcome was more convincing in the 
milder 5058-Hemi hybrid SMA mice, which provided a wider 
therapeutic window. In fact, treatment of 5058-Hemi hybrid 
SMA mice with 3UP8i produced improvements in weight and 
survival that began to mirror the efficacy of larger ISS-N1 
targeting ASOs reported recently. Although it is difficult to 
pinpoint the exact cause of the 5058-Hemi hybrid’s lessened 
severity, we suspect that this was the result of hybrid vigor. 
The noticeable caveat of this model is the development of 
hind limb edema. This pathology limits the types of motor 
tests that can be performed. Central nervous system (CNS) 
administration of ISIS-SMNRx, an ISS-N1 targeting MOE 
ASO, into SMA type III mice (5058-4copy) rescued a simi-
lar phenotype,29 which may explain why peripheral admin-
istration routes were unable to correct this necrosis. The 
improvements in the Hemi-hybrid SMA mice corresponded to 
increased FL-SMN2 transcript and total SMN levels at P12. 
The P50 3UP8i-treated SMA mice showed decreased FL-
SMN2 transcript and SMN levels compared to levels at P12, 
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yet they were functionally normal aside from mild necrosis 
and decreased body size. Previous studies have indicated 
that the need for increased SMN levels is more critical at 
early as opposed to later time periods.18
While previous studies have demonstrated the effective-
ness of very small ASOs (7-mer-11-mer) in vitro,41,42 our find-
ings with 3UP8i validate, for the first time, the therapeutic 
potential of a very small splice switching oligonucleotide in 
an animal model of a human disease. In addition to a bet-
ter uptake, a small ASO imparts greater efficacy, provided 
it maintains target specificity.43–45 Considering 3UP8i did not 
tolerate a single mismatch with the target, it fulfilled one of 
the rigorous requirements of target specificity. Future studies 
will be aimed at determining global off target effects of 3UP8i, 
particularly at higher concentrations. This information will be 
valuable for SMA research and more generally regarding the 
effects of short ASOs as they are developed for the treatment 
of other human diseases. The small helix generated by the 
annealing of 3UP8i to the GCRS is predicted to disrupt ISTL1 
that we recently reported to be an inhibitory RNA structure 
formed by a unique LDI.22 Hence, the mechanism of 3UP8i 
function is likely to be distinct from the group of ISS-N1 target-
ing ASOs that displace inhibitory protein(s) hnRNP A1/A2.21,46 
To further underscore the promising therapeutic potential of 
3UP8i, it did not elicit an inflammatory response, as mea-
sured by qRT-PCR of common inflammation markers AIF1, 
CD68, IL-1A, IFNA, and IL-18 (Supplementary Figure S4). 
Our results also establish the potential of combining new 
chemistries to further enhance 3UP8i efficacy. In a broader 
context, our results validate the ability of a short ASO (8-mer) 
to correct a human disease in an animal model. This has 
important implications for the development of other therapeu-
tics directed at small targets, including seed sequences of 
microRNAs, where the use of large ASOs carries the risk of 
poor specificity.
Materials and methods
Mice. Animals were cared for and monitored in accordance 
with the approved Lurie Children’s Hospital Institutional Ani-
mal Care and Use Committee protocols. Animals were kept 
in a controlled environment at 25 °C and 50% humidity, with 
a 12 hours light/dark photoperiod, and were monitored daily 
for health. Three SMA mouse models were utilized in this 
study (see Supplementary Table S1): 5058- homozygous 
mice (SMN2tg/o;SMN2tg/o;Smntm1Hung/tm1Hung) were generated 
as described;28,29 5058-Hemi FVB/N SMA mice (SMN2tg/
o;Smntm1Hung/tm1Hung) were generated as described;18,27 5058-
Hemi hybrid SMA mice (SMN2tg/o; Smntm1Hung/tm1.1Jme) were 
generated by crossing 5058-homozygous FVB/N mice 
(SMN2tg/o;SMN2tg/o;Smntm1Hung/tm1Hung) with the heterozygous 
mice harboring the Δ7Smn Melki allele (Smntm1.1Jme/Wt; C57-con-
genic), which produces litters in which 50% of the pups are 
SMA. The resulting SMA mice are FVB/N:C57/BL6 F1- 
hybrids, hemizygous for the SMN2 allele and compound het-
erozygotes for the Δ7Smn allele (SMN2tg/o;Smntm1Hung/tm1.1Jme). 
All offspring were genotyped on P0 using multiplex PCR 
of tail biopsies as previously described.28 Mice were culled 
or combined to maintain litter sizes between six and nine 
pups, with at least two heterozygous siblings per cage. When 
possible, each cage of SMA mice under study (5058-Hemi 
FVB/N and 5058-Hemi hybrid) was evenly split between mis-
match control (CON8i) and 3UP8i, which were delivered as 
blinded drugs known as oligo A and oligo B. One caveat of 
note was that by P6 or later, 3UP8i-treated 5058-hemizygous 
mice could often be unblinded based on weight and righting 
reflex.
Drug treatments and phenotyping. The 3UP8i and mismatch 
control (CON8i) 8-mer ASOs incorporated 2′OMeP, with 
a 5′ PEG-282 modification (Spacer 18) and a 3′ C3-propyl 
spacer, were synthesized (TriLink Technologies, San Diego, 
CA) as previously described.16,21 ASOs were resuspended in 
0.9% saline and passed through a 0.22 μm filter. Samples 
were coded as oligo A or oligo B to blind the studies. Mice 
were dosed on P0, P5, and P10 at either 20 or 80 μg/g of 
body weight via IP injection. Mice were monitored every 
morning for survival, weight, righting reflex (5058-Hemi only), 
and ECG (5058-Hemi hybrid only). For the righting reflex 
test, mice were placed in a supine position and assayed for 
the time-to-right on all four paws. Failure to right was set at 
60 seconds. Functional death was defined as two consecu-
tive days of greater than 20% weight loss or righting reflex 
failure. Noninvasive ECG measurements of conscious 5058-
Hemi hybrid mice were recorded between P8 and P18, using 
the ECGenie system (Mouse Specifics, Quincy, MA) as previ-
ously described.35,47
RNA and protein analysis. Total RNA was isolated from 
50 mg of tissue using the TRIzol reagent (Life Technologies, 
Carlsbad, CA) as per the manufacturer’s instructions. DNase 
treatment and first-strand cDNA synthesis were performed 
as previously described.48 FL- and Δ7-SMN2 end point PCR 
was performed as previously described.29 Cycle conditions: 
94 °C/45 seconds, 60 °C/45 seconds, 72 °C/45 seconds, 30 
cycles. TaqMan assays of FL- and Δ7-SMN2 were performed 
on an Applied Biosystems (Carlsbad, CA) 7500 Fast Real-
Time PCR System utilizing the following conditions: 1 cycle: 
2 minutes 50 °C, 1 cycle: 10 minutes 95 °C, 40 cycles: 15 
seconds 95 °C, 1 minutes 60 °C. The data were analyzed 
using the ΔΔCt method. Primer and probe sets used were 
previously described.29 Mouse Gapdh (#4352339E, Applied 
Biosystems) was used to normalize samples. The data were 
analyzed using the ΔΔCt method.49 Radioactive RT-PCR 
was performed as previously described.21 5058-Hemi hybrid 
mouse tissue was collected and homogenized as previously 
described.50 Lysates were analyzed via immunoblot using the 
Li-COR Odyssey (Li-COR Technologies, Lincoln, NE) system 
as previously described.48
Immunostaining and microscopy. NMJ staining and imag-
ing of whole-mount intercostal (IC) muscles from P12 5058-
Hemi hybrid mice were performed as previously described.32 
Images were blinded and randomized prior to the analysis of 
NMJ motor endplate area and innervation status. Innervation 
status was determined as previously described.28 Motor end-
plate area was defined by measuring the area of the back-
ground-subtracted of the α-BTX-594 signal using NIH Image 
J software (National Institutes of Health, Bethesda, MD). For 
each pup, n = 50 or more NMJs were analyzed.
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Statistical analysis. Statistical analyses were performed 
using Graph Pad Prism software, V6.0 (GraphPad Software, 
La Jolla, CA). Kaplan–Meier survival curves were compared 
using log-rank tests. Statistical significance was determined 
using either a one- or two-way analysis of variance with a 
Bonferroni posthoc comparison, or Student’s t-test when 
appropriate.
Supplementary material
Figure S1. Effect of 3UP8i treatment on splicing of SMN2 
in vivo.
Figure S2. 3UP8 improves cardiac deficits in Hemi-hybrid 
SMA mice.
Figure S3. 3UP8i increases FL-SMN2 levels in skeletal 
muscle of Hemi-hybrid SMA mice.
Figure S4. 3UP8i ASO does not increase expression of 
several inflammation-related genes.
Table S1. SMA models utilized in this study.
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